Get the Stockscreener App
3.11
1.58%
-0.05
Tempest Therapeutics Inc stock is traded at $3.11, with a volume of 49,150.
It is down -1.58% in the last 24 hours and down -64.25% over the past month.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
See More
Previous Close:
$3.16
Open:
$3.16
24h Volume:
49,150
Relative Volume:
0.48
Market Cap:
$15.32M
Revenue:
-
Net Income/Loss:
$-43.10M
P/E Ratio:
-0.3199
EPS:
-9.7212
Net Cash Flow:
$-36.82M
1W Performance:
-0.32%
1M Performance:
-64.25%
6M Performance:
-56.26%
1Y Performance:
-71.34%
1-Day Range:
$3.0601
$3.19
1-Week Range:
$3.04
$3.23
52-Week Range:
$3.00
$13.65
Tempest Therapeutics Inc Stock (TPST) Company Profile
Name
Tempest Therapeutics Inc
Sector
Industry
Phone
415-798-8589
Address
2000 SIERRA POINT PARKWAY, BRISBANE
Compare TPST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TPST
Tempest Therapeutics Inc
|
3.11 | 15.57M | 0 | -43.10M | -36.82M | -9.7212 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-10-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Feb-08-24 | Initiated | Jefferies | Buy |
Tempest Therapeutics Inc Stock (TPST) Latest News
Tempest Therapeutics (TPST) Stock Price, Quote, News & History - Benzinga
Tempest Therapeutics closes $4.25 million registered direct offering By Investing.com - Investing.com Nigeria
Tempest Therapeutics Closes $4.3 Million Direct Offering - MarketScreener
Tempest Therapeutics closes $4.25 million registered direct offering - Investing.com
Tempest Therapeutics : Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules - MarketScreener
Tempest Therapeutics, Inc. Completes Registered Direct Offering and Private Placement, Raising Approximately $4.25 Million - Quiver Quantitative
Tempest Announces Closing of Up To $8.35 Million Registered - GlobeNewswire
[8-K] Tempest Therapeutics, Inc. Reports Material Event | TPST SEC FilingForm 8-K - Stock Titan
Tempest Therapeutics Secures $4.25M in Direct Offering - MSN
Form 8-KCurrent report - ADVFN
Tempest Therapeutics stock falls after $4.25 million direct offering - MSN
[424B5] Tempest Therapeutics, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
Form 424B5 Tempest Therapeutics, - StreetInsider
Tempest Therapeutics stock falls after $4.25 million direct offering By Investing.com - Investing.com UK
Tempest Therapeutics raises $4.25 million in registered direct offering - Investing.com
Tempest Therapeutics Inc (TPST) Performance and Fundamentals Dashboard tells a completely different story - setenews.com
Tempest Therapeutics raises $4.25 million in registered direct offering By Investing.com - Investing.com South Africa
Tempest Therapeutics (Nasdaq: TPST) prices $4.25M offering with $4.1M warrant upside - Stock Titan
Is Tempest Therapeutics Inc. stock ready for breakoutMarket Growth Report & Growth Oriented Trade Recommendations - newser.com
Will Tempest Therapeutics Inc. stock outperform growth indexesTrend Reversal & Fast Exit/Entry Strategy Plans - newser.com
Tempest Therapeutics Announces New Leadership and Acquisition - MSN
Tempest Therapeutics to acquire Factor Bioscience’s CAR-T programs By Investing.com - Investing.com Australia
Check Out Tempest Therapeutics Inc (TPST)’s Trade Data Rather Than the Analysts’ Views - Setenews
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Tempest Therapeutics stock plunges after all-stock acquisition By Investing.com - Investing.com Australia
What technical signals suggest for Tempest Therapeutics Inc. stockJuly 2025 Sentiment & Expert Curated Trade Ideas - newser.com
Will Tempest Therapeutics Inc. stock go up soonProduct Launch & Safe Entry Trade Signal Reports - newser.com
Tempest Therapeutics Stock Plummets Nearly 50% Amid Shareholder Dilution Fears Following CAR-T Acquisition - Markets Financial Content
Tempest gains CAR Ts for 65% of the company; stock drops - BioWorld MedTech
Why Tempest Therapeutics Inc. stock appeals to dividend seekersQuarterly Portfolio Report & Verified Momentum Watchlists - newser.com
Tempest Therapeutics to acquire Factor Bioscience's CAR-T programs By Investing.com - Investing.com Nigeria
Is Tempest Therapeutics Inc. stock poised for growthWeekly Trade Analysis & Scalable Portfolio Growth Ideas - newser.com
TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction - MSN
Tempest Therapeutics to acquire Factor Bioscience’s CAR-T programs - Investing.com India
Why Tempest Therapeutics (TPST) Stock Is Down 45% Today - Benzinga
Tempest Therapeutics stock plunges after all-stock acquisition - Investing.com India
Is Tempest Therapeutics Inc. stock undervalued vs historical averages2025 Top Decliners & Expert Approved Trade Ideas - newser.com
Is Tempest Therapeutics Inc. stock cheap at current valuationJuly 2025 Selloffs & Risk Controlled Daily Plans - newser.com
Tempest announces strategic acquisition of new dual-car T programs from Factor with simultaneous runway extension projected to mid 2027 - marketscreener.com
Tempest Therapeutics Announces Executive and Board Changes - TradingView
Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027 - The Globe and Mail
Tempest Therapeutics Inc Stock (TPST) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):